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In this issue of Cancer Cell, Rubin et al. (2011) describe using various conditional mouse models to trace
the developmental origin and genetic basis of rhabdomyosarcomas. Their work provides a genetic dissec-
tion underlying rhabdomyosarcomas development and unveils unexpected relationship between various
soft-tissue tumor types.Rhabdomyosarcomas (RMSs) are the
predominant soft-tissue tumors of chil-
dren and adolescents (Arndt and Crist,
1999). These tumors are generally divided
into alveolar rhabdomyosarcoma (aRMS)
and embryonal rhabdomyosarcoma
(eRMS) subtypes. Most aRMSs are the
result of chromosomal translocations be-
tweenPAX3 or PAX7 and FOXO1A genes,
resulting in Pax3-FKHR and Pax7-FKHR
fusion proteins (Tiffin et al., 2003). These
fusion proteins have potent transcrip-
tional activity leading to cellular transfor-
mation and oncogenesis into aRMS. On
the other hand, a wide range of causative
mutations have been implicated in eRMS,
such as the loss of heterozygosity at
11p15.5 locus (Anderson et al., 1999),
mutations in tumor suppressor p53
(Felix et al., 1992), retinoblastoma (Rb1)
(Kohashi et al., 2008), N- and K-ras genes
(Stratton et al., 1989), and PTCH1 hap-
loinsuficiency (Hahn et al., 1998).
It is thought that eRMSs develop from
cells residing within the muscle tissue,
partly because eRMSs express markers
of muscle cells such as MyoD, Myogenin,
and Desmin. Furthermore, these tumors
can also occur where muscle tissue re-
sides. However, muscle tissue contains a
heterogeneous population of muscle
stem cells and downstream myogenic
progenitors as well as nonmyogenic cells
(Kuang et al., 2007). To study the poten-
tials of individual subpopulations of mus-
cle cells in eRMS development, Rubin
et al. (2011) deleted p53 either with or
without Ptch1 haploinsuficiency. They
then used various Cre drivers to inactivate
these genes in muscle stem cells and in
proliferating and maturing myoblasts. In
a 600 day follow-up period, they observedthat all mouse Cre lines developed tumors
at the penetrance rate of 13%–56%.
Upon histological examination of these
tumors, they found a spectrum of malig-
nancies ranging from alveolar and embry-
onal RMS to undifferentiated pleomorphic
sarcomas (UPSs). They observed that
rhabdomyosarcomas developed from all
subpopulations of muscle cells, including
muscle satellite cells and differentiating
myoblasts (Figure 1). More importantly,
they found that the cell of origin and the
mutational profile of the tumors were
important in determining the proportion
of rhabdomyosarcomas versus undiffer-
entiated spindle cell sarcomas (i.e.,
UPSs). Loss of p53 in maturing myoblasts
(Myf6+ cells) gave rise to the highest
percentage of eRMSs. These tumors
showed the highest degree of myogenic
differentiation potential, while those
derived from satellite cells (Pax7+ cells)
had the lowest rate of myogenic differen-
tiation in in vitro differentiation assays.
To study the effect of retinoblastoma
(Rb1) mutation on eRMS development in
combination with the loss of p53, Rubin
et al. (2011) inactivated both p53 and Rb1
with or without Ptch1 haploinsuficiancy.
Loss of Rb1 alone did not lead to tumor
initiation. However, unlike Rb1 loss, Ptch1
haploinsuficiency contributed to tumor
initiation at every level of cellular differenti-
ation. To further explore the role of Rb1 in
rhabdomyosarcomas development, they
inactivated both Rb1 and p53 in various
subpopulations of muscle progenitor cells
using different Cre drivers. Surprisingly,
they observed that combination of Rb1
and p53 loss was generally associated
with an undifferentiated phenotype in the
resulting tumors. Rb1 deletion reducedCancer Cell 19,the myodifferentiation potentials of p53
null tumor cells. Based on these observa-
tions, Rb1 seems to act as a modifier of
tumor phenotype, in part by regulating the
proliferation rate of sarcomacells. Interest-
ingly, analysis of the global gene expres-
sion profiling showed a marked difference
between tumors with intact versus mutant
Rb1. These findings further support the
conclusion that Rb1 may act as modifier
in sarcoma development, potentially by
regulating a broad range of genetic and
transcriptional networks.
Perhaps one of the most intriguing
aspects of this study by Rubin et al.
(2011) is that at least a subset of eRMS
andUPS tumors seem to share a common
cell of origin. This is interesting, as UPS
tumors, a broad range of heterogeneous
neoplasms including malignant fibrous
histiocytomas or undifferentiated spindle
cell sarcomas have a poorly defined
etiology. These tumors also show no
obvious signs of differentiation by immu-
nohistochemical and molecular criteria.
On the other hand, eRMSs express a
broad range of muscle cell markers and
possess myodifferentiation potentials.
Their data further show that while ma-
turing myoblasts are more prone to giving
rise to eRMS tumors, UPS tumors are
more likely to develop fromPax7 express-
ing muscle satellite cells. Furthermore,
irrespective of the cell of origin, Rb1
modifies tumor phenotype to mimic UPS
(Figure 1). Therefore, UPSs and eRMSs
may constitute a continuum of the same
disease.
By comparative analysis and global
gene expression profiling, Rubin et al.
(2011) delineate gene expression signa-
ture for UPS and eRMS and show thatFebruary 15, 2011 ª2011 Elsevier Inc. 157
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Figure 1. The Developmental Origin and Mutational Profile of the Tumor Determine the
Proportions of RMS
Different subpopulations of myogenic precursor cells give rise to RMS. While p53 deletion and Ptch1
haploinsufficiency are important players in cellular transformation and myodifferentiation potential of
the resulting tumor, Rb1 deletion acts as a modifier of tumor phenotype in that context. Tumors (i.e.,
eRMSs) arising from different cells of origin exhibit the same gene expression profile as that of the
activated muscle satellite cells.
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PreviewseRMSs have a similar gene signature with
that of the activated muscle satellite cell
(Figure 1). This finding is interesting for
two reasons: first, it shows that gene
expression pattern is not a predictor of
the cell of origin, as eRMSs develop
from a range of muscle cells, including
muscle satellite cells and downstream
myogenic progenitors such as maturing
myoblasts, as shown in this study.
Second, it implies that the cohort of muta-
tions giving rise to eRMS likely results in
a broad reprogramming of the transcrip-
tional network of the transformed cells,
making it to resemble gene signature of
the activated satellite cells.
The study by Rubin et al. (2011)
provides important new insight into the
genetic basis of rhabdomyosarcomas in
the context of p53, Rb1, and Ptch1muta-
tional pathways, and shows the potential
of various subpopulations of muscle158 Cancer Cell 19, February 15, 2011 ª2011stem cells and downstream myogenic
precursors in rhabdomyosarcomas devel-
opment. Importantly, this study opens
a forum for addressing other fundamental
questions in the future. For example, to
assess the relevance of their mouse
sarcoma models to the human disease,
Rubin et al. (2011) studied the gene ex-
pression profile of 111 primary human fu-
sion-negative rhabdomyosarcomas from
public databases and found that in at least
29% of cases they were unable to identify
a gene signature in line with their mouse
sarcoma models. The authors rightly
argue that theremight be additional muta-
tions involving other tumor suppressors
that may be involved in rhabdomyosar-
comas development. Indeed, there is
recent evidence indicating that other
tumor suppressor genes such as PTEN
may also play a role in sarcoma develop-
ment (Gibault et al., 2011). In addition,Elsevier Inc.given the observation that muscle stem
cells and the downstream myogenic pre-
cursors can give rise to eRMS as demon-
strated in this study does not preclude
the possibility of other nonmuscle cells to
contribute to the disease, as also empha-
sized by the authors. The conclusions
from this study and previouswork suggest
that the genetic basis of rhabdomyosar-
comas, especially that of the eRMS, is
complex and is likely defined by a wide
range of genetic and epigenetic factors.
The heterogeneity in rhabdomyosar-
comas phenotype may therefore be the
result of the balance between the muta-
tional profile of the tumor and the cell of
origin. The involvement of tumormodifiers
such as Rb1 in changing sarcoma pheno-
type as shown in this study raises many
interesting questions about the possibility
of yet other unknown modifiers and the
genetic context in which these modifiers
exert their effect on shaping the tumor
phenotype. Future studies involving com-
parative genetic and epigenetic analysis
of these tumors may provide a more
concrete understanding of a cohort of
potential players in rhabdomyosarcomas
development. The feasibility and relative
affordability of large scale genomic se-
quencing platforms provide opportunities
to perform comparative genome-wide
analysis in large sets of tumor samples in
search of these genetics or epigenetic
factors. In addition, a role for posttran-
scriptional gene regulation by microRNAs
in rhabdomyosarcomas development has
also been demonstrated (Wang et al.,
2008). Further studies on the role of
microRNAs in sarcomas development
are another avenue that is important to
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The outgrowth of metastatic cells to bone depends on the interaction between multiple intrinsic and host
factors. In this issue of Cancer Cell, Sethi and colleagues report Notch signaling in bone cells as responsible
for promoting this outgrowth and provide evidence for a beneficial treatment effect of NOTCH inhibitors.Metastasis, the last and most devastating
stage of tumor progression, remains the
cause of 90% death in cancer patients.
The development of metastases requires
a series of sequential rate-limiting steps
through which malignant tumor cells
from the primary site invade into blood
and lymphatic vasculature, survive in the
circulation, lodge at distant organs, and
outgrow. The revised ‘‘seed and soil’’
theory, originally proposed by Steven
Paget a century ago, hypothesizes that
the outcome of metastasis depends on
crosstalk between predetermined cancer
cells (the ‘‘seeds’’) and specific organ
microenvironments (the ‘‘soil’’), which
release homeostatic factors (Fidler and
Poste, 2008). In the soil organ, the seed
cancer cells can enter either latent phase
or outgrowth phase.
The skeletal system is recognized as the
habitat of the hematopoietic stem cell as
well as the most common metastatic site
for breast cancer. Recently, a positive
feedback loop causing a ‘‘vicious cycle’’
has been identified, in which the out-
growth phase of the bone metastases is
determined by a bidirectional interaction
between the cancer cells and the bone
microenvironment. This crosstalk involves
growth factors and cytokines derived from
both host and cancer cells (Figure 1) (Kang
et al., 2003; Zhang et al., 2009).Seventy percent of breast cancer
patients are affected by bone metastasis,
manifested by skeletal-related events
such as severe bone pain and patholog-
ical fractures (Mundy, 2002). There is
much evidence that metastatic cancer
cells usurp the normal process of bone re-
modeling through stimulation of both
osteoclasts that resorb bone and osteo-
blasts that deposit bone, and the net
outcome of lesions depends on the
relative contribution of each cell type. In
the outgrowth (or osteolytic) phase,
multiple growth factors, including trans-
forming growth factor b (TGFb) and
insulin-like growth factor 1 (IGF1), are
released from the degraded bone matrix.
TGFb and IGF1 both enhance the growth
of cancer cells and stimulate them to
produce several cytokines, including
parathyroid hormone-related protein
(PTHrP), connective tissue growth factor
(CTGF), and interleukin 11 (IL11). PTHrP
and IL11 regulate the expression of osteo-
clastogenic factors receptor activator of
nuclear factor-kB ligand (RANKL) and os-
teoprotegerin (OPG) in osteoblasts,
whereas CTGF mediates both angiogen-
esis and invasion (Massague, 2008).
Additional cells, such as bone borrow-
derived stromal, endothelial, and hemato-
poietic cells, have all been shown to
contribute to the development of themac-rometastases and the production of
prometastatic factors (Joyce and Pollard,
2009). On the other hand, the processes
by which metastatic cancer cells directly
communicate with various types of cells
in the bone and bone marrow remains
an enigma in the field of bone metastasis.
Undoubtedly, fully answering such ques-
tions will provide the insight necessary
for the development of effective therapies
against bone metastasis.
Sethi et al. (2011) now provide both
experimental and preclinical evidence
that the Notch ligand Jagged1 plays
a critical role in the promotion of bone
metastatic outgrowth of breast cancer.
Using a bioinformatic approach that
correlates the gene expression pattern
of Notch signaling pathway components
(ligands, receptors, and downstream
targets) to bone metastasis, the authors
indentified a unique upregulation of
Jagged1, which was highly correlated
with human breast cancer metastases
to bone. To investigate the functional
role of Jagged1 in the development of
bone metastasis, the authors applied
two different types of Jagged1-express-
ing human breast cancer cell lines in
a xenograft mouse model. In the strongly
bone tropic cell lines with high levels of
Jagged1 expression, stable knockdown
of Jagged1 resulted in a reduction ofFebruary 15, 2011 ª2011 Elsevier Inc. 159
